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Both the recognition of HIV-infected cells and the immunogenicity of candidate CTL
vaccines depend on the presentation of a peptide epitope at the cell surface, which in
turn depends on intracellular antigen processing. Differential antigen processing maybe
responsible for the differences in both the quality and the quantity of epitopes pro-
duced, influencing the immunodominance hierarchy of viral epitopes. Previously, we
showed that the magnitude of the HIV-2 gag-specific T-cell response is inversely corre-
lated with plasma viral load, particularly when responses are directed against an epitope,
165DRFYKSLRA173, within the highly conserved Major Homology Region of gag-p26. We
also showed that the presence of three proline residues, at positions 119, 159 and 178 of
gag-p26, was significantly correlated with low viral load. Since this proline motif was also
associated with stronger gag-specific CTL responses, we investigated the impact of these
prolines on proteasomal processing of the protective 165DRFYKSLRA173 epitope. Our data
demonstrate that the 165DRFYKSLRA173 epitope is most efficiently processed from precur-
sors that contain two flanking proline residues, found naturally in low viral-load patients.
Superior antigen processing and enhanced presentationmay account for the link between
infection with HIV-2 encoding the “PPP-gag” sequence and both strong gag-specific CTL
responses as well as lower viral load.
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Introduction
Despite approximately 30–60% nucleotide sequence homology
between HIV-1 and HIV-2, HIV-2 infection is characterized by
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slower disease progression, with survival being unaffected by
HIV-2 status for many infected adults [1]. Moreover, it was
recently shown that preexisting HIV-2 infection may confer some
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Table 1. Sequence of peptides containing the immunodominant epitope DRFYKSLRA (DA9)
Peptide name HIV strain Position in gaga) Position in
capsid-p26/p24
within gag
Sequence (5′-3′)b)
P1: HIV-2-PP HIV-2 285-318 151-184 DIKQGPKEPFQSYVDRFYKSLRAEQTDPAVKNWM
P2: HIV-2-SA HIV-2 285-318 151-184 DIKQGPKESFQSYVDRFYKSLRAEQTDAAVKNWM
P3: HIV-1-PQ HIV-1 284-317 152-185 DIRQGPKEPFRDYVDRFYKTLRAEQATQEVKNWM
a)Amino acid position with respect to HIV-1-HXB2 (acc no. K03455) and HIV-2 ROD (acc no. M15390).
b)Amino acid in flanking sequence is in bold and shaded, other amino acid substitutions are underlined and in italics.
protection against HIV-1 disease progression [2]. Although the
proviral load is similar between HIV-1- and HIV-2-infected peo-
ple at the same stage of infection [3, 4], plasma viral load is
significantly lower in most people with HIV-2 infection [5, 6].
However, a minority of HIV-2-infected people develop a syn-
drome characterized by high levels of plasma virus and rapid
CD4+ T-cell decline [7], leading to a clinical picture indistin-
guishable from AIDS caused by HIV-1 [8]. Thus HIV-2 presents
the intriguing model of a human retrovirus with which most
infected people become long-term nonprogressors. The discrep-
ancy between the plasma and proviral load in most HIV-2-infected
patients is compatible with enhanced immune control of viral
replication, or defective HIV-2 replicative capacity, or a combi-
nation of both mechanisms. Elucidating the reasons for the rel-
atively attenuated course of HIV-2 infection, and identifying the
key differences between HIV-2 progressors and nonprogressors,
could shed light on the mechanisms of HIV-1 pathogenesis and
provide a better understanding of protective immunity to HIV
infection.
Cytotoxic T lymphocytes (CTLs) play a central role in host
defense against intracellular pathogens by destroying infected
cells presenting peptides processed from the pathogen. CTLs rec-
ognize and bind to processed peptides 8–11 residues long that are
presented bymajor histocompatibility complex (MHC) I molecules
[9]. The role of CTLs in controlling HIV-1 infection has been well
established, with strong supporting evidence [9]. The suppressive
role of CTLs during HIV-1 infection is highlighted by viral evasion
of immune mechanism via downregulation of host MHC I [10];
andmutating within or close to defined CTL epitopes [11], thereby
avoiding CTL recognition.
Both the recognition of HIV-infected cells and the immuno-
genicity of candidate CTL vaccines depend on the presentation of
an epitope peptide at the cell surface [12], which in turn depends
on intracellular antigen processing. Differential antigen process-
ing may contribute to both the quantity and quality of epitopes
produced [12]. Studies in animal models have shown that the
efficiency of antigen processing can influence the hierarchy of
viral epitopes, suggesting that poorly processed epitopes with a
low affinity for the transporter associated with antigen process-
ing (TAP) will be less likely to enter the ER and be loaded onto
the MHC [12–14], and are therefore less likely to be presented
to CTLs. In addition, artificial mutations in flanking regions of
mouse viral epitopes [15–18] or naturally occurring mutations in
the flanking region of HIV [19, 20] and HCV [21] epitopes have
been shown to impair antigen processing and presentation, lead-
ing to CTL escape. Le Gall et al. found that a single amino acid
change in the flanking sequence of an epitope can either reduce
or augment the CTL response significantly [12].
Much less is known about the role of the HIV-2-specific CTL
response and there have been no reports of the development
of HIV-2 “escape” mutants selected under CTL pressure. Previ-
ous studies from our group have shown that HIV-2-specific CTL
responses have a broader range of functions, particularly at low
antigen concentrations, than HIV-1-specific T cells [22, 23]. Viral
control is significantly associated with CD8+ T-cell responses to
gag [22]: the magnitude of the HIV-2 gag-specific T-cell response
is inversely correlated with plasma viral load; particularly when
responses are directed against a highly conserved 18 amino acid
region of the gag p26 protein, referred to as “peptide 46” [23].
Peptide 46 (Gag298–315, YVDRFYKSLRAEQTDPAV) is located in the
major homology region of the gag protein, a 20-residue sequence
at the C-terminal domain of the gag capsid [24]. This sequence is
highly conserved throughout primate lentiviruses and even among
most known retroviruses. This evolutionary conservation strongly
suggests that the major homology region plays an important role
in the retroviral structure and replication [24, 25]. The HIV-1
major homology region contains a number of known MHC class
I and class II restricted epitopes. One of the well-characterized
epitopes within peptide 46 is a nonamer, DRFYKTLRA [25, 26] in
HIV-1, and DRFYKSLRA in HIV-2, herein referred to as HIV-1 DA9
(nonamer (9-mer) epitope within HIV-2 gag, with the sequence
DRFYKSLRA) or HIV-2 DA9, respectively. The HIV-1 epitope was
first reported as the dominant HLA B-14-restricted CTL response
in a long-term nonprogressor, infected for over 20 years with HIV-
1[25, 26].
An association between the presence of a motif-containing 3
prolines (P) residues at positions 119, 159, and 178 of the HIV-2
capsid (positions 254, 294, and 313, respectively, of HIV-2 gag
gene product, Table 1) and viral control was previously observed
in this study population [27]. Interestingly, the last two prolines
are in the flanking region of the DA9 epitope within peptide 46,
[PFQSYVDRFYKSLRAEQTDPAV].We therefore hypothesized that
the presence of prolines in the flanking region of peptide 46 could
modulate the quality and quantity of the DA9 epitope generated
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and therefore affect the magnitude and specificity of the T-cell
response.
Results
PPP sequence within HIV-2 capsid is significantly
correlated with a higher T-cell response magnitude
Ex vivo IFN-γ ELISpot assays were performed using PBMC from
HIV-2-infected subjects stimulated with 15–19 amino acid long
peptides, overlapping by 10 amino acids and spanning a con-
sensus sequence for the HIV-2 clade A proteome [23]. The level
of immune response (IFN-γ production), measured in SFU/106
cells, was compared in patients infected with HIV-2 whose gag
sequences have the PPP motif flanking the peptide 46 region and
those with non-PPP sequences. The same samples were used for
both the ELISpot assays and viral sequencing. The results revealed
that high magnitude T-cell responses were significantly correlated
with the presence of the PPP motif, for both responses against
the entire HIV-2 proteome (Fig. 1A) and gag-specific responses
(Fig. 1B). All patients were HLA typed and of the 20 subjects
tested five (25%) were HLA-B14 positive. All HLA-B14 subjects
made strong IFN-γ peptide 46-specific responses. Three of the five
HLA-B14 subjects had the top highest responses and the remaining
two were in the top half of responders (data not shown).
The CD8+ T-cell epitope within peptide 46 is a
nonamer, DRFYKSLRA (DA9)
Peptide truncations were generated (Fig. 2A) and used in an ex
vivo ELISpot, at a final peptide concentration of 2μg/mL, together
with PBMCs from five HLA-B14-positive peptide 46 responders
(CD8+ T-cell response), to determine the optimal epitope. Pep-
tides 46-21 and 46-22 have the same sequence, DRFYKSLRA, but
were made by different companies. The strongest response was
observed with the truncated 9-mer peptide, 165DRFYKSLRA173;
suggesting that this peptide represents the optimal epitope
(Fig. 2B). In addition, HLA-B14 tetramer-sorted CD8+ T-cell
clones, all specific for the DA9 epitope, were successfully obtained
from three of the five samples. This result was not surprising, as
the equivalent epitope has been previously documented as a CTL
epitope in HIV-1-infected donors with HLA-B14 [25, 26].
In vitro generation of DA9 epitope precursor is more
efficient for the HIV-2PP peptide
To evaluate the effect of the PP motif present in the flanking
regions of the DA9 epitope on antigen processing, we synthesized
three 34-mer peptides containing the DA9 epitope in the middle.
To generate our peptides, we aligned HIV-2 p26 sequences from
Caio, Guinea Bissau, accession numbers: GQ485448-GQ485516
[27], as well as other HIV-2 p26 sequences from different HIV-2
groups available online. Using these alignments, we designed two
representative HIV-2 peptides (Table 1), differing by only two
amino acids at positions 159 and 178. HIV-2-PP represents a 34-
mer HIV-2 peptide containing prolines at positions 159 and 178;
and HIV-2-SA represents another 34-mer HIV-2 peptide of the
same sequence except it is flanked by serine (S) and alanine (A)
at positions 159 and 178 (S and A are the most common amino
acids, apart from prolines, at positions 159 and 178; see Materi-
als and methods). HIV-1-PQ is an equivalent HIV-1 peptide from
the HXB2 (accession no: K03455) sequence. We subjected these
peptides to in vitro digestion with highly purified proteasome (iso-
lated from human erythrocytes) and immunoproteasome (isolated
from human spleen) and analyzed the proteolysis products by
tandem mass spectrometry. Semiquantitative information for the
relative abundance of peptide species observed between different
experimental conditions was obtained by comparing Mascot pep-
tide Mowse scores. We computed the number of peptide cleavage
products that were at most 24 amino acids long and still con-
tained the DA9 epitope (epitope precursors); and reported them
as Hits (the number of epitope precursors with less than 25 amino
acids long that contain the intact DA9 epitope); and Scores (the
sum of peptide identification confidence (Mascot Mowes) scores
of peptides less than 25 amino acids long containing the DA9 epi-
tope). After 40 min of digestion with proteasome, we observed six,
three, and three epitope precursors for the HIV-2-PP, HIV-2-SA,
and HIV-1-PQ peptides, respectively (Fig. 4A). The 70-min pro-
teasomal digestion yielded three, two, and two epitope precursors
for the HIV-2-PP, HIV-2-SA, and HIV-1-PQ peptides, respectively
(Figs. 3 and 4B). At both time points, the HIV-2-PP peptide yielded
the epitope precursors with the highest scores, followed by HIV-
2SA and HIV-1PQ (Figs. 3 and 4). Digestion with the immuno-
proteasome was generally more efficient (Figs. 3 and 4) in our
experiment, yielding seven, five, and four epitope precursors after
40 min and nine, seven, two precursors after 70 min for the HIV-
2-PP, HIV-2-SA, and HIV-1-PQ peptide precursors, respectively.
Following the same trend, the HIV-2-PP peptide digested with the
immunoproteasome generated epitope precursors with the high-
est scores, which were much higher than those observed with the
corresponding proteasome digestions (Fig. 4).
Taken together, both the proteasomal and immunoproteaso-
mal digestions produced more N- and C-terminally extended DA9
precursors derived from the HIV-2-PP peptide as compared to the
HIV-2-SA peptide. Also, both HIV-2 peptides produced more pre-
cursors than the equivalent HIV-1 peptide (Fig. 3). These epitope
precursors will further undergo N-terminal cleavage and exact
C-terminal cleavage before being transported to the ER for fur-
ther processing and loading onto MHC I molecules for antigen
presentation on the cell surface.
Exact C-terminal cleavage was most efficient for the
HIV-2 peptide with the PP motif
Proteasomes effectively and precisely cleave CTL epitope pep-
tides at the C-terminal end [28] and may leave an N-terminal
C© 2015 The Authors. European Journal of Immunology published by
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Figure 1. Relationship between IFN-γ response of HIV-infected subjects and the presence or absence of prolines at positions 119, 159, and 178 of
the HIV-2 gag (p26) capsid protein. PBMCs from HIV-infected subjects were stimulated with (A) the entire HIV-2 proteome or (B) HIV-2 gag p26 and
IFN-γ production was measured by ELISpot. Each dot represents the response from one individual; 51 samples were assayed once. The average of
the spots from the control wells were subtracted from all the sample wells before computing the SFU/106 PBMCs. Black horizontal bars represent
median values, and significant P values are indicated. Statistical significance calculated using nonparametric Wilcoxon/Mann–Whitney U test.
extension that can be further trimmed by aminopeptidases in the
cytoplasm or endoplasmic reticulum (ER) to generate peptides 8–
11 amino acids in length [29]. In addition, a large cytosolic pep-
tidase, tripeptidyl peptidase II (TPPII) removes groups of three
residues from the N-terminus of peptides at least 16 amino acids
long [30]. Although C- andN-terminally extended peptidesmay be
generated and transported into the ER, only those with N-terminal
extensions are presented by MHC I [31]. Thus, we analyzed the
fragments for exact C-terminal cleavage. Mass spectrometry anal-
ysis revealed that for both the proteasomal and immunoproteaso-
mal digestions, the HIV-2-PP peptide was cleaved most efficiently
at the C-terminus, followed by HIV-1-PQ, and cleavage was least
Figure 2. The CD8+ T-cell epitope within peptide 46 is a nonamer, DRFYKSLRA (DA9). Truncations of peptide 46 (YVDRFYKSLRAEQTDPAV) were
generated and used in an ex vivo ELISpot together with PBMCs from five HLA-B14-positive, peptide 46 responders (CD8+ T-cell response), to
determine the epitope length. (A) The sequences of the truncated peptides are shown. The optimal epitope DA9 sequence is highlighted in gray;
peptides 46-21 and 46-22 have the same sequence, DRFYKSLRA, but were made by different companies. (B) Truncated peptides were used in ex
vivo IFN-γ ELISpot assays to determine the optimal CD8+ T-cell restricted epitope within peptide 46. Each bar represents the number of cells
producing IFN-γ measured in SFU/106 PBMCs. This figure is a representative plot from one individual, assayed once. Four donors were evaluated.
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Figure 3. Digestion products of the HIV-2-PP, HIV-2-SA, and HIV-1-PQ peptides analyzed by tandem mass spectrometry. The three 34-mer
peptides—HIV-2-PP, HIV-2-SA, and HIV-1-PQ—were subjected to in vitro digestion with highly purified proteasome and immunoproteasome for
(A) 40 min and (B) 70 min. Proteolysis products were evaluated by tandem mass spectrometry to measure production efficiency. The proteolytic
products containing intact DA9 sequences, called epitope precursors, are shown for each digestion experiment. The amino acid substitutions in
the HIV-2-PP, HIV-2-SA, and HIV-1-PQ peptides are in bold and underlined, other differences in sequence are underlined, and DA9 in each epitope
precursor is bold. The dots around the start and end of the sequences represent the N- and C- terminal cleavage sites, respectively.
efficient for HIV-2-SA, and this was observed at all time points
(Fig. 5).
The exact nonamer epitope (DA9) was produced only
from the HIV-2 peptide with the PP motif
Previous research has indicated that some MHC I molecules can
directly bind peptides generated by either the proteasomes or
immunoproteasome and transport them to the ER using TAP [32],
while other extended peptides are further trimmed in the ER or
cytosol. Those further trimmed in the cytosol have to reenter the
peptide-loading complex and compete with newly translocated
peptides [32]. Since exact C-terminal cleavage is necessary for
presentation, we further analyzed the N-terminal cleavages of
peptides with a perfect C-terminal cleavage, by considering up
to 14 extra residues extending from the N-terminal of the DA9
epitope. N-terminal processing was also most efficient with the
HIV-2-PP peptide with exact or short N-terminal extensions, fol-
lowed by HIV-1-PQ and, again, worst for HIV-2-SA (Figs. 3 and
6). Analysis of the peptides showed that the generation of the
exact 9-mer, DA9 (N-terminal extension = 0), was indeed only
present in digests from the HIV-2-PP peptide, with the immuno-
proteasome after both the 40- and 70-min digestions (Fig. 6). In
addition, a 10-mer (1+ DA9) N-terminal extended peptide was
found after 70 min digestion of the HIV-2-PP peptide with the
immunoproteasome (Figs. 3 and 6)
The immunoproteasome is much more efficient in
generating the DA9 epitope in vitro
While the proteasome is adept at processing peptides for class I
presentation, the immunoproteasome is much more efficient at
this process [33]. Immunoproteasome cleavage is characterized
by reduced cleavage after acidic residues and increased cleavage
after basic and large hydrophobic residues, which are favored by
TAP and found in peptides efficiently bound to MHC I molecules
[33]. In our experiments, we employed both types because it
has been observed that, in some instances, it is the proteasome
and not the immunoproteasome that generates certain epitopes
[33]. We found that both the proteasome and immunoprotea-
some generated the N- and C-terminal extended epitope precur-
sors (Fig. 4), but the immunoproteasome produced much higher
relative amounts of the epitope precursors and was able to pro-
duce the exact C- and N-terminal cleavages including the exact
9-mer epitope (Figs. 3 and 6).
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Figure 4. In vitro generation of DA9 epitope precursor is more efficient for the HIV-2PP peptide. The three 34-mer peptides—HIV-2-PP, HIV-2-
SA, and HIV-1-PQ—were subjected to in vitro digestion with highly purified proteasome and immunoproteasome for (A) 40 min and (B) 70 min.
Proteolysis products were evaluated by tandemmass spectrometry tomeasure production efficiency. P1: HIV-2-PP represents 34-mer HIV-2 peptide
containing prolines at positions 159 and 178; P2: HIV-2-SA represents another 34-mer HIV-2 peptide of the same sequence except it is flanked by
serine (S) and alanine (A) at positions 159 and 178; and P3: HIV-1-PQ is an equivalent HIV-1 34-mer peptide from the HXB2 sequence (accession
no: K03455). Semiquantitative information for the relative abundance of peptide species observed between different experimental conditions was
obtained by comparing Mascot peptide Mowse scores. Hits (*) or epitope precursors represent the “number” of peptides <25 amino acids long that
contain the intact DA9 epitope (Fig. 3). Score (**): represents the “sum” of peptide identification confidence (Mascot Mowes) scores of peptides <25
amino acids long containing the DA9 epitope. Data are presented as Mascot peptide Mowse scores and data shown are from a single experiment.
Discussion
This study shows that the presence of prolines in the flanking
region of peptide 46 influences the quality and quantity of the DA9
epitope generated. The HIV-2-PP and HIV-2-SA peptides differ by
only two amino acids (P159S and P178A), yet both proteaso-
mal and immunoproteasomal digestions produce the DA9 epitope
more efficiently for HIV-2-PP, which has two flanking prolines.
The superior antigen processing of HIV-2-PP relative to HIV-2-
SA is shown by the higher abundance of DA9 epitope precursors,
exact C-terminal cleavage, better N-terminal cleavage, and gener-
ation of the optimal 9-mer epitope. These results indicate that the
Figure 5. Exact C-terminal cleavage was most efficient for the HIV-2 peptide with the PP motif. The three 34-mer peptides—HIV-2-PP, HIV-2-SA,
and HIV-1-PQ—were subjected to in vitro digestion with highly purified proteasome and immunoproteasome for (A) 40 min and (B) 70 min.
Proteolysis products were evaluated by tandem mass spectrometry to measure efficient C-terminal cleavage. P1: HIV-2-PP, P2: HIV-2-SA, and P3:
HIV-1-PQ are the 34-mer peptide sequences as described in the legend of Figure 4 or Table 1. Hits (*) and Score (**) are defined as for Figure 4. Data
are presented as Mascot peptide Mowse scores and data shown are from a single experiment.
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Figure 6. The exact nonamer epitope (DA9) is produced only from the HIV-2 peptide with the PP motif. The three 34-mer peptides generated from
epitope DA9—HIV-2-PP, HIV-2-SA, and HIV-1-PQ—were subjected to in vitro digestion with highly purified proteasome and immunoproteasome
for (A) 40 min and (B) 70 min. Proteolysis products were evaluated by tandem mass spectrometry to measure the quantity of peptides produced
with exact C-terminal cleavage, and with N-terminal extensions of up to 14 residues. P1: HIV-2-PP, P2: HIV-2-SA, and P3: HIV-1-PQ are the 34-mer
peptide sequences as described in the legend of Figure 4 or Table 1. Hits (*) and Score (**) are defined as for Figure 4. Data are presented as Mascot
peptide Mowse scores and data shown are from a single experiment.
significant correlation previously found between the presence of
prolines at positions 119, 159, and 178 in the HIV-2 capsid and
low viral load [27], as well as the strong gag-specific responses in
patients infected with HIV-2 viruses with the PPP capsid both cor-
relate with superior antigen processing in vitro of the DA9 epitope
flanked by two proline residues.
The role of CTLs in the control of HIV-1 replication is well
established and has led to numerous efforts to generate candidate
HIV vaccines that would elicit potent CTL responses. However, due
to the difficulties of using whole virus, most studies use peptide
pulsing to detect or quantify CTL responses. Although useful for
screening studies, this approach overlooks a few critical steps in
the antigen-processing pathway [12]. A limitation to our study is
that in vivo, peptides generated by the proteasome or immunopro-
teasome may be later subjected to further degradation by cytosolic
peptidases, and hence it cannot be excluded that the DA9 epitope
within the extended peptides or even the actual epitope, observed
in our studies, may be destroyed before it is presented. However,
due to the central role the proteasome plays in epitope generation,
and the fact that the proteasome has been known to generate
correctly cleaved epitopes that are presented [33–35], indicates
that in vitro proteasomal digestions can be reliably used [36–38].
Upon discovery of a significant correlation between responses to
peptide 46 and HIV-2 viral control, we tried to decipher why only
some individuals responded to this epitope and not others, despite
a high degree of epitope conservation. The observation that the
presence of prolines flanking this HLA-B14 epitope was also linked
to HIV-2 control indicated that differential antigen processing due
to prolines in the flanking region may explain the response, or
lack thereof, to peptide 46, irrespective of epitope conservation.
We performed in vitro proteasomal degradation of long synthetic
peptides and found that antigen processing plays an important role
in the generation of the HIV-2 DA9 epitope. The peptide with two
flanking prolines, HIV-2-PP, was processed much more efficiently
than both HIV-2-SA and HIV-1-PQ. Even though for the HIV-2-SA
peptide, we observed more epitope precursors than for the HIV-
1 peptide, HIV-1-PQ, processing was more efficient for HIV-1-PQ
because both the C- and N- terminal cleavages responsible for
DA9 epitope generation occurred more efficiently for HIV-1-PQ.
Thus we conclude that both the previously observed correlations
between the presence of three prolines in the HIV-2 capsid and
low viral load, and the greater magnitude T-cell responses in indi-
viduals infected with HIV-2 strains that have these prolines in the
region flanking the DA9 epitope (HIV-2-PP), reflect the superior
antigen processing of the HIV-2-PPP gag protein by the immuno-
proteasome.
Proline is unique among the other 19 amino acids in that it
is the only cyclic amino acid (its amine nitrogen is not bound to
a hydrogen atom within peptide sequences). Furthermore proline
residues can adopt cis/trans-peptide bonds, requiring cells to uti-
lize prolyl isomerases to facilitate protein folding [39]. These fea-
tures and its cyclic nature mean that proline is unique structurally
in a way that makes it important in protein folding. The cyclic
structure locks its  backbone making it conformationally rigid,
such that when found within secondary structures such as alpha
helices and beta sheets, it forms a kink in the helix or sheet, dis-
rupting their stability and structure [39, 40]. The prolines flanking
the DA9 epitope are located in the C′-end of the capsid, involved
in dimer formation and capsid shell assembly [41]. Onyango et al.
modeled and generated p26 capsid proteins including various
combinations of proline residues observed in the HIV-2 isolates
from Caio; and upon comparing the binding energies of the dif-
ferent capsids, found that PPP capsids had statistically weaker
binding energies compared to those without prolines [27]. The
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lower binding energy of the PPP capsid suggests lower dimer sta-
bility that may also have consequences for antigen processing, and
this mechanism may be additive to the direct influence on proteo-
somal processing that was documented in the current study [23].
Unstable proteins are probably more susceptible to proteasomal
degradation, leading to better processing and therefore presenta-
tion of epitopes from such proteins [42] and hence the presence
of prolines flanking an epitope may increase epitope production
via this mechanism. In linear sequences, the presence of proline at
a cleavage site (P1) usually inhibits proteolysis, as most proteases
do not accept proline at this site [43, 44]. However, the presence
of proline at P2 or P4 can sometimes promote proteolysis at the
cleavage site (P1-P1′) [44, 45].
Several HIV vaccines are in various stages of development.
These include CTL vaccines made up of strings of conserved HIV
dominant or subdominant epitopes in an immunogenic vector. Our
study shows that sequence conservation of an epitope is not suf-
ficient for it to be immunogenic; and that the flanking sequences
also need to be taken into account as they may profoundly influ-
ence efficient processing and presentation. It may be the case
that the presence of prolines flanking certain epitopes can result
in better antigen processing; this could be further explored in the
generation of HIV epitope vaccines. Future studies focusing on the
elucidation of the mechanisms of viral control in HIV-2 infection,
as well as a better understanding of the factors governing epitope
processing and presentation, will be useful in vaccine design and
in the development of new therapeutics against HIV infection.
Materials and methods
Study population
The Caio´ cohort in rural Guinea Bissau was initiated in 1988
to study the epidemiology of HIV-2 infection. Since then, sev-
eral serosurveys of the entire community have been performed to
record incident HIV-1/2 infection. Between each serosurvey, HIV-
infected individuals were followed up more regularly and had free
access to clinical care. All cohort members were antiretroviral ther-
apy naive until the introduction of antiretroviral therapy in 2007
as part of the national program in Guinea-Bissau. HIV-2 infected
individuals were sampled from this cohort as previously described
[23, 27]. Study participants provided consent; the joint Gambian
Government Medical Research Council Ethics Committee and the
National AIDS Control Programme Committee of Guinea Bissau
approved the studies.
Ex-vivo IFN-γ ELISpot assays
A total of 96-well MultiScreen filter plates (Millipore) were
coated with 15 μg/mL of anti-IFN-γ monoclonal antibody (1-
DIK, Mabtech). A total of 105 PBMCs/well in 80 μL of H10
medium (RPMI 1640, 10% human AB serum, 2 mM L-glutamine,
50 U/mL penicillin/streptomycin [Sigma Aldrich]) were added to
the plates. Cells were then stimulated with 20 μL of 10 μg/mL
of peptide for 16 h as previously described [23]. Spots on the
plates were counted using an AID ELISpot reader system (Autoim-
mun Diagnostika GmbH). Results were expressed as spot forming
units (SFU)/106 PBMCs. Each dot represents the response from
one individual; 51 samples were assayed once. The average of the
spots from the control wells were subtracted from all the sample
wells before computing SFU/106 PBMCs. Results were regarded
as positive if they were at least three times the mean of the qua-
druplicate negative control wells and over 50 SFU/106 PBMCs. If
background wells were more than 30 SFU/106 PBMCs or if both
positive control wells (phytohemagglutinin or FEC stimulation)
were negative, the assay was excluded from further analysis. Pep-
tides based on truncations of peptide 46 were generated (Fig. 2A)
and used in an ex vivo ELISpot assay, at a final peptide concentra-
tion of 2 μg/mL, together with PBMCs from five HLA-B14 positive
peptide 46 responders (CD8+ T-cell response). Peptides 46-21 and
46-22 have the same sequence, DRFYKSLRA, but were made by
different companies.
Peptide design
By stratifying capsid sequences according to the presence or
absence of prolines at positions 119, 159, and 178 of the HIV-2
capsid, Onyango et al. found a significant correlation with low
plasma viral load [27]. At position 119, the other amino acids
present were alanine (n = 38), glutamine (n = 5), or glycine
(n = 1); at position 159 the nonproline amino acids were ser-
ine (n = 29) and threonine (n = 2); and at the last position,
178, there were alanine (n = 18), serine (n = 2), glutamine
(n = 1), and valine (n = 1). To generate our peptides, we aligned
HIV-2 p26 sequences from Caio, Guinea Bissau, accession num-
bers: GQ485448–GQ485516 [27], first according to response to
peptide 46, and then in order of increasing viral load in each
group (responders and nonresponders). We also included HIV-2
p26 sequences from different HIV-2 groups available online. Using
these alignments, we designed two representative HIV-2 peptides
(Table 1), each 34 amino acids long, but differing by only two
amino acids at positions 159 and 178, respectively, one with two
prolines159/178 (PP) and the other with serine159 and alanine178 (S
and A are themost common amino acids at positions 159 and 178).
HIV-1-PQ is an equivalent HIV-1 34-mer peptide from the HXB2
sequence (accession no: K03455). The long peptides were each
produced to >99% purity (Biomatik, Ontario, Canada). Individ-
ual truncated peptides used in ELISpot assays were synthesized
in-house by 9-fluorenylmethoxy carbonyl (Fmoc) chemistry, at
the Weatherall Institute of Molecular Medicine, the University of
Oxford and the peptide sequences confirmed by MALDI-TOF/TOF
mass spectrometry analysis.
In vitro proteasomal digestion
Highly purified 20S proteasome (cat no: BML-PW8720-0050),
isolated from human erythrocytes and 20S immunoproteasome
C© 2015 The Authors. European Journal of Immunology published by
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(BML-PW9645-0050) isolated from human spleen, bought from
Biomol International, Enzo Life sciences, were used in our exper-
iments. The certificates of analysis included Western blots to
show the purity of the proteasomes and immunoproteasomes. One
microgram of either purified human or was added to 10 μg of
each 34-mer oligopeptide in a final volume of 100 μL of prote-
olysis buffer (20 mM HEPES (pH 7.8), 2 mM magnesium acetate
and 2 mM dithiothreitol) and incubated at 37°C in 5% CO2 for 0,
40, and 70 min, after which the reaction was stopped by adding
10 μL formic acid. The samples were kept frozen at −80°C until
analysis [36]. To eliminate nonspecific degradation, we included
two sets of controls in each experiment: one with peptide only,
without enzymes (proteasome or immunoproteasome) in the pro-
teolytic buffer and the other with enzymes included, but with
formic acid added immediately to stop the enzymatic reaction.
Digested samples were desalted using C18 Zip-tip (Millipore)
according to the manufacturer’s instructions and concentrated
by vacuum centrifugation. Samples were then analyzed by nano-
liquid chromatography mass spectrometry using a nano-Acquity
UPLC coupled to a Waters quadruple time-of-flight (Q-Tof) Pre-
mier tandem mass spectrometer (Waters, Milford, MA, USA) as
described previously [46]. To determine peptide precursors, frag-
ment identification and peptide quantification, the instrument
was configured to analyze data in high/low collision switching
(MSE) mode [46]. ProteinLynx Global Server Software (v.2.3)
was used to convert MSE data into MS/MS spectra. The MS/MS
spectra (peaklists) were searched against modified databases con-
taining SwissProt database (release version 54.0, 07/2007, num-
ber of entries 276 256) with additional custom HIV-1 and HIV-2
sequences using Mascot version 2.2 (Matrix science, London, UK).
In addition, individual MS/MS spectra for peptides with a Mas-
cot Mowse score lower than 40 (Expect < 0.015) were inspected
manually and included in the quantification only if a series of at
least four continuous y or b-ions were observed, according to pub-
lished guidelines [47, 48]. The local “in-house” Mascot server used
for this study is supported and maintained by the Computational
Biology Research Group at the University of Oxford. Semiquanti-
tative information for the relative abundance of peptide species
observed between different experimental conditions was obtained
by comparing Mascot peptide Mowse scores [48]. The controls,
no enzyme added or digestion stopped immediately, were used to
eliminate potential degradation products.
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